

- Moyer VA, US Preventive Services Task Force. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. *Ann Intern Med* 2014;160.
- Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 2010;28:893–901.
- Amir E, Freedman OC, Seruga B, et al. Assessing women at high risk of breast cancer: a review of risk assessment models. *J Natl Cancer Inst* 2010;102:680–691.
- Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. *Science* 1994;266:66–71.
- Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. *Science* 1994;265:2088–2090.
- Lux MP, Fasching PA, Beckmann MW. Hereditary breast and ovarian cancer: review and future perspectives. *J Mol Med* 2006;84:16–28.
- Shannon KM, Chittenden A. Genetic testing by cancer site: breast. *Cancer J* 2012;18:310–319.
- Guillem JG, Wood WC, Moley JF, et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. *J Clin Oncol* 2006;24:4642–4660.
- Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57:75–89.
- Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. *JAMA* 2010;304:967–975.
- US Equal Employment Opportunity Commission. Genetic information discrimination. <http://www.eeoc.gov/laws/types/genetic.cfm>. Accessed January 2, 2014.
- Society of Surgical Oncology. Position statement on prophylactic mastectomy. <http://www.surgonc.org/practice-policy/practice-management/consensus-statements/position-statement-on-prophylactic-mastectomy>. Accessed February 1, 2014.
- Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. *N Engl J Med* 1999;340:77–84.
- Eldor L, Spiegel A. Breast reconstruction after bilateral prophylactic mastectomy in women at high risk for breast cancer. *Breast J* 2009;15:S81–S89.
- Zakhireh J, Fowble B, Esserman LJ. Application of screening principles to the reconstructed breast. *J Clin Oncol* 2010;28:173–180.
- Gabram SG, Dougherty T, Albain KS, et al. Assessing breast cancer risk and providing treatment recommendations: immediate impact of an educational session. *Breast J* 2009;15:S39–S45.
- Nadauld LD, Ford JM. Molecular profiling of gastric cancer: toward personalized cancer medicine. *J Clin Oncol* 2013;31:838–839.
- Bardram L, Hansen TV, Gerdes AM, et al. Prophylactic total gastrectomy in hereditary diffuse gastric cancer: identification of two novel CDH1 gene mutations—a clinical observational study. *Fam Cancer* 2014;13:231–242.
- Norton JA, Ham CM, Van Dam J, et al. CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Ann Surg* 2007;245:873–879.
- Lynch HT, Grady W, Suriano G, et al. Gastric cancer: new genetic developments. *J Surg Oncol* 2005;90:114–133, discussion 133.
- Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. *Nature* 1998;392:402–405.
- Kaurah P, MacMillan A, Boyd N, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 2007;297:2360–2372.
- Benusiglio PR, Malka D, Rouleau E, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicenter study. *J Med Genet* 2013;50:486–489.
- Gaya DR, Stuart RC, Going JJ, et al. Hereditary diffuse gastric cancer associated with E-cadherin mutation: penetrance after all. *Eur J Gastroenterol Hepatol* 2008;20:1249–1251.
- Lee KH, Hwang D, Kang KY, et al. Frequent promoter methylation of CDH1 in non-neoplastic mucosa of sporadic diffuse gastric cancer. *Anticancer Res* 2013;33:3765–3774.
- Oliveira C, Sousa S, Pinheiro H, et al. Quantification of epigenetic and genetic 2nd hits in CDH1 during hereditary diffuse gastric cancer syndrome progression. *Gastroenterology* 2009;136:2137–2148.
- Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. *J Pathol* 2004;203:681–687.
- Huntsman DG, Carneiro F, Lewis FR, et al. Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *N Engl J Med* 2001;344:1904–1909.
- Suriano G, Yew S, Ferreira P, et al. Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clin Cancer Res* 2005;11:5401–5409.
- Rogers WM, Dobo E, Norton JA, et al. Risk-reducing total gastrectomy for germline mutations in E-cadherin (CDH1): pathologic findings with clinical implications. *Am J Surg Pathol* 2008;32:799–809.
- Worster E, Liu X, Richardson S, et al. The impact of prophylactic total gastrectomy on health-related quality of life: a prospective cohort study. *Ann Surg* 2014;260:87–93.
- Lim YC, di Pietro M, O'Donovan M, et al. Prospective cohort study assessing outcomes of patients from families fulfilling criteria for hereditary diffuse gastric cancer undergoing endoscopic surveillance. *Gastrointest Endosc* 2014;80:78–87.
- Mavaddat N, Peock S, Frost D, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *J Natl Cancer Inst* 2013;105:812–822.
- Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 2001;68:700–710.
- Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. *N Engl J Med* 1997;336:1401–1408.
- Finch AP, Lubinski J, Moller P, et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. *J Clin Oncol* 2014;32:1547–1553.
- Walsh T, Casadei S, Lee MK, et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. *Proc Natl Acad Sci U S A* 2011;108:18032–18037.
- Couch FJ, Wang X, McGuffog L, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genet* 2013;9:e1003212.
- Schrader KA, Hurlbert J, Kalloger SE, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. *Obstet Gynecol* 2012;120:235–240.
- Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2002;346:1609–1615.
- Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. *N Engl J Med* 2002;346:1616–1622.
- Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. *J Clin Oncol* 2008;26:1331–1337.
- Folkins AK, Jarboe EA, Roh MH, et al. Precursors to pelvic serous carcinoma and their clinical implications. *Gynecol Oncol* 2009;113:391–396.
- Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). *Int J Gynecol Cancer* 2013;23:1603–1611.
- Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. *JAMA* 2011;305:2304–2310.
- Leenen CH, van Lier MG, van Doorn HC, et al. Prospective evaluation of molecular screening for Lynch syndrome in patients with endometrial cancer ≤ 70 years. *Gynecol Oncol* 2012;125:414–420.
- Resnick K, Straughn JM Jr, Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. *Obstet Gynecol* 2009;114:530–536.
- Watson P, Vasen HF, Mecklin JP, et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. *Am J Med* 1994;96:516–520.
- Koomstra JJ, Mourits MJ, Sijmons RH, et al. Management of extracolonic tumours in patients with Lynch syndrome. *Lancet Oncol* 2009;10:400–408.
- Dove-Edwin I, Boks D, Goff S, et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. *Cancer* 2002;94:1708–1712.
- Schmeler KM, Lynch HT, Chen LM, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. *N Engl J Med* 2006;354:261–269.
- Yang KY, Caughey AB, Little SE, et al. A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary nonpolyposis colorectal cancer (HNPCC) Families. *Fam Cancer* 2011;10:535–543.
- Pistorius S, Kruger S, Hohl R, et al. Occult endometrial cancer and decision making for prophylactic hysterectomy in hereditary nonpolyposis colorectal cancer patients. *Gynecol Oncol* 2006;102:189–194.
- Traugott AL, Moley JF. Multiple endocrine neoplasia type 2: clinical manifestations and management. *Cancer Treat Res* 2009;153:321–337.
- American Thyroid Association Guidelines Task Force, Kloos RT, Eng C, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. *Thyroid* 2009;19:565–612.
- Wells SA Jr, Pacini F, Robinson BG, et al. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. *J Clin Endocrinol Metab* 2013;98:3149–3164.
- Eng C, Clayton D, Schuffenecker I, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. *JAMA* 1996;276:1575–1579.

58. Howe JR, Norton JA, Wells SA Jr. Prevalence of pheochromocytoma and hyperparathyroidism in multiple endocrine neoplasia type 2A: results of long-term follow-up. *Surgery* 1993;114:1070–1077.
59. Machens A, Niccoli-Sire P, Hoegel J, et al. Early malignant progression of hereditary medullary thyroid cancer. *N Engl J Med* 2003;349:1517–1525.
60. Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2A associated with cutaneous lichen amyloidosis. *Ann Intern Med* 1989;111:802–806.
61. Santoro M, Carlomagno F, Romano A, et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. *Science* 1995;267:381–383.
62. Mulligan LM, Ponder BA. Genetic basis of endocrine disease: multiple endocrine neoplasia type 2. *J Clin Endocrinol Metab* 1995;80:1989–1995.
63. Mulligan L, Kwok J, Healy C. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A). *Nature* 1993;363:458–460.
64. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. *Hum Mol Genet* 1993;2:851–856.
65. Traugott AL, Moley JF. The RET Protooncogene. *Cancer Treat Res* 2010;153:303–319.
66. Quayle FJ, Benveniste R, DeBenedetti MK, et al. Hereditary medullary thyroid carcinoma in patients greater than 50 years old. *Surgery* 2004;136:1116–1121.
67. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. *N Engl J Med* 1994;331:828–835.
68. Niccoli-Sire P, Murat A, Baudin E, et al. Early or prophylactic thyroidectomy in MEN 2/FMTC gene carriers: results in 71 thyroidectomized patients. The French Calcitonin Tumours Study Group (GETC). *Eur J Endocrinol* 1999;141:468–474.
69. Rodriguez CJ, Balsalobre MD, Pomares F, et al. Prophylactic thyroidectomy in MEN 2A syndrome: experience in a single center. *J Am Coll Surg* 2002;195:159–166.
70. Skinner MA, Moley JA, Dilley WG, et al. Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A. *N Engl J Med* 2005;353:1105–1113.
71. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. *J Clin Endocrinol Metab* 2001;86:5658–5671.
72. Elisei R, Romei C, Renzini G, et al. The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. *J Clin Endocrinol Metab* 2012;97:426–435.
73. Waguespack SG, Rich TA, Perrier ND, et al. Management of medullary thyroid carcinoma and MEN2 syndromes in childhood. *Nat Rev Endocrinol* 2011;7:596–607.
74. Moley JF. Medullary thyroid carcinoma: management of lymph node metastases. *J Natl Compr Canc Netw* 2010;8:549–556.
75. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. *J Clin Endocrinol Metab* 2010;95:2655–2663.
76. Solorzano CC, Evans DB. Same-day ultrasound guidance in reoperations for locally recurrent papillary thyroid cancer. *Surgery* 2007;142:973–975.
77. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. *Curr Gastroenterol Rep* 2012;14:428–438.
78. Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. *Int J Cancer* 2006;119:807–814.
79. Russell AM, Zhang J, Luz J, et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. *Int J Cancer* 2006;118:1937–1940.
80. Jaspersion KW. Genetic testing by cancer site: colon (polyposis syndromes). *Cancer J* 2012;18:328–333.
81. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). *N Engl J Med* 2005;352:1851–1860.
82. Lynch HT, Lynch PM, Lanspa SJ, et al. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. *Clin Genet* 2009;76:1–18.
83. Vasen HF, Blanco I, Aktan-Collan K, et al. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. *Gut* 2013;62:812–823.
84. Niessen RC, Hofstra RM, Westers H, et al. Germline hypermethylation of MLH1 and EPCAM deletions are a frequent cause of Lynch syndrome. *Genes Chromosomes Cancer* 2009;48:737–744.
85. Kuiper RP, Vissers LE, Venkatchalam R, et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. *Hum Mutat* 2011;32:407–414.
86. Rumilla K, Schowalter KV, Lindor NM, et al. Frequency of deletions of EPCAM (TACSTD1) in MSH2-associated Lynch syndrome cases. *J Mol Diagn* 2011;13:93–99.
87. Jaspersion KW, Tuohy TM, Neklason DW, et al. Hereditary and familial colon cancer. *Gastroenterology* 2010;138:2044–2058.
88. Steinhagen E, Markowitz AJ, Guillem JG. How to manage a patient with multiple adenomatous polyps. *Surg Oncol Clin N Am* 2010;19:711–723.
89. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening*. http://www.nccn.org/professionals/physician_gls/pdf/colorectal_screening.pdf. Accessed February 19, 2014.
90. Vasen HF, Moslein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). *Cut* 2008;57:704–713.
91. Church J. Familial adenomatous polyposis. *Surg Oncol Clin N Am* 2009;18:585–598.
92. Nieuwenhuis MH, Bulow S, Bjork J, et al. Genotype predicting phenotype in familial adenomatous polyposis: a practical application to the choice of surgery. *Dis Colon Rectum* 2009;52:1259–1263.
93. Sinha A, Tekkis PP, Rashid S, et al. Risk factors for secondary proctectomy in patients with familial adenomatous polyposis. *Br J Surg* 2010;97:1710–1715.
94. Koskenvuo L, Renkonen-Sinisalo L, Jarvinen HJ, et al. Risk of cancer and secondary proctectomy after colectomy and ileorectal anastomosis in familial adenomatous polyposis. *Int J Colorectal Dis* 2014;29:225–230.
95. Remzi FH, Church JM, Bast J, et al. Mucosectomy vs. stapled ileal pouch-anal anastomosis in patients with familial adenomatous polyposis: functional outcome and neoplasia control. *Dis Colon Rectum* 2001;44:1590–1596.
96. Friederich P, de Jong AE, Mathus-Vliegen LM, et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. *Clin Gastroenterol Hepatol* 2008;6:1237–1242.
97. Aziz O, Athanasiou T, Fazio VW, et al. Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis. *Br J Surg* 2006;93:407–417.
98. Fazio VW, Kiran RP, Remzi FH, et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. *Ann Surg* 2013;257:679–685.
99. Rajaratnam SC, Eglinton TW, Hider P, et al. Impact of ileal pouch-anal anastomosis on female fertility: meta-analysis and systematic review. *Int J Colorectal Dis* 2011;26:1365–1374.
100. Bartels SA, D'Hoore A, Cuesta MA, et al. Significantly increased pregnancy rates after laparoscopic restorative proctocolectomy: a cross-sectional study. *Ann Surg* 2012;256:1045–1048.
101. Beyer-Berjot L, Maggiori L, Birnbaum D, et al. A total laparoscopic approach reduces the infertility rate after ileal pouch-anal anastomosis: a 2-center study. *Ann Surg* 2013;258:275–282.
102. Steinhagen E, Guillem JC, Chang C, et al. The prevalence of thyroid cancer and benign thyroid disease in patients with familial adenomatous polyposis may be higher than previously recognized. *Clin Colorectal Cancer* 2012;11:304–308.
103. Steinhagen E, Hui VW, Levy RA, et al. Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients. *Am J Surg* [ePub ahead of print].
104. Jarrar AM, Milas M, Mitchell J, et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. *Ann Surg* 2011;253:515–521.
105. Giardiello FM, Burt RW, Jarvinen H, et al. Familial adenomatous polyposis. In: Bosman FT, Carneiro F, Hruban RH, et al, eds. *Classification of Tumours of the Digestive System*. Lyon: IARC Press; 2010:147–151.
106. Nieuwenhuis MH, Lefevre JH, Bulow S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. *Dis Colon Rectum* 2011;54:1229–1234.
107. Quintini C, Ward G, Shatnawei A, et al. Mortality of intra-abdominal desmoid tumors in patients with familial adenomatous polyposis: a single center review of 154 patients. *Ann Surg* 2012;255:511–516.
108. Sinha A, Gibbons DC, Phillips RK, et al. Surgical prophylaxis in familial adenomatous polyposis: do pre-existing desmoids outside the abdominal cavity matter? *Fam Cancer* 2010;9:407–411.
109. Schiessling S, Kihm M, Ganschow P, et al. Desmoid tumour biology in patients with familial adenomatous polyposis coli. *Br J Surg* 2013;100:694–703.
110. von Roon AC, Tekkis PP, Lovegrove RE, et al. Comparison of outcomes of ileal pouch-anal anastomosis for familial adenomatous polyposis with and without previous ileorectal anastomosis. *Br J Surg* 2008;95:494–498.
111. Nieuwenhuis MH, Vogt S, Jones N, et al. Evidence for accelerated colorectal adenoma–carcinoma progression in MUTYH-associated polyposis? *Cut* 2012;61:734–738.
112. Palomaki GE, McClain MR, Melillo S, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med* 2009;11:42–65.
113. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. *J Natl Cancer Inst* 2004;96:261–268.
114. Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. *Gastroenterology* 1999;116:1453–1456.
115. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. *N Engl J Med* 2006;354:2751–2763.
116. Lee-Kong SA, Markowitz AJ, Glogowski E, et al. Prospective immunohistochemical analysis of primary colorectal cancers for loss of mismatch repair protein expression. *Clin Colorectal Cancer* 2010;9:255–259.
117. Steinhagen E, Shia J, Markowitz AJ, et al. Systematic immunohistochemistry screening for Lynch syndrome in early age-of-onset colorectal cancer patients undergoing surgical resection. *J Am Coll Surg* 2012;214:61–67.

118. Heald B, Plesec T, Liu X, et al. Implementation of universal microsatellite instability and immunohistochemistry screening for diagnosing lynch syndrome in a large academic medical center. *J Clin Oncol* 2013;31:1336–1340.
119. Beamer LC, Grant ML, Espenschied CR, et al. Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results. *J Clin Oncol* 2012;30:1058–1063.
120. Mvundura M, Grosse SD, Hampel H, et al. The cost-effectiveness of genetic testing strategies for Lynch syndrome among newly diagnosed patients with colorectal cancer. *Genet Med* 2010;12:93–104.
121. Chen S, Wang W, Lee S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA* 2006;296:1479–1487.
122. Kastrinos F, Steyerberg EW, Mercado R, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. *Gastroenterology* 2011;140:73–81.
123. Green RC, Parfrey PS, Woods MO, et al. Prediction of Lynch syndrome in consecutive patients with colorectal cancer. *J Natl Cancer Inst* 2009;101:331–340.
124. Khan O, Blanco A, Conrad P, et al. Performance of Lynch syndrome predictive models in a multi-center US referral population. *Am J Gastroenterol* 2011;106:1822–1827, quiz 1828.
125. Tresallet C, Brouquet A, Julie C, et al. Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. *Int J Cancer* 2012;130:1367–1377.
126. Kalady MF, McGannon E, Vogel JD, et al. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. *Ann Surg* 2010;252:507–511, discussion 511–513.
127. Parry S, Win AK, Parry B, et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. *Gut* 2011;60:950–957.
128. Kalady MF, Lipman J, McGannon E, et al. Risk of colonic neoplasia after proctectomy for rectal cancer in hereditary nonpolyposis colorectal cancer. *Ann Surg* 2012;255:1121–1125.
129. Cirillo L, Urso ED, Parrinello G, et al. High risk of rectal cancer and of metachronous colorectal cancer in probands of families fulfilling the Amsterdam criteria. *Ann Surg* 2013;257:900–904.
130. Stupart DA, Goldberg PA, Baigrie RJ, et al. Surgery for colonic cancer in HNPCC: total vs segmental colectomy. *Colorectal Dis* 2011;13:1395–1399.
131. Maeda T, Cannom RR, Beart RW Jr, et al. Decision model of segmental compared with total abdominal colectomy for colon cancer in hereditary nonpolyposis colorectal cancer. *J Clin Oncol* 2010;28:1175–1180.
132. Guillem JG, Glogowski E, Moore HG, et al. Single-amplicon MSH2 A636P mutation testing in Ashkenazi Jewish patients with colorectal cancer: role in presurgical management. *Ann Surg* 2007;245:560–565.
133. Barrow P, Khan M, Lalloo F, et al. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. *Br J Surg* 2013;100:1719–1731.
134. Vasen HF, Abdirahman M, Brohet R, et al. One to 2-year surveillance intervals reduce risk of colorectal cancer in families with Lynch syndrome. *Gastroenterology* 2010;138:2300–2306.
135. Stuckless S, Green JS, Morgenstern M, et al. Impact of colonoscopic screening in male and female Lynch syndrome carriers with an MSH2 mutation. *Clin Genet* 2012;82:439–445.
136. Engel C, Rahner N, Schulmann K, et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. *Clin Gastroenterol Hepatol* 2010;8:174–182.
137. Syngal S, Weeks JC, Schrag D, et al. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. *Ann Intern Med* 1998;129:787–796.
138. Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. *Dis Colon Rectum* 2014; 57(8):1025–1048.